牛牛AI助理已提取核心訊息
NeuroSense Therapeutics, a clinical-stage biotechnology company, reported a net loss of $10.1 million for the year ended December 31, 2023, compared to a net loss of $10.5 million for the previous year. The company's research and development expenses increased by 30.2% to $7.3 million, primarily due to clinical study costs and an increase in employee numbers. General and administrative expenses slightly decreased by 3.9% to $4.8 million. Financing income netted a gain of $1.9 million, mainly from the revaluation of warrants. As of December 31, 2023, NeuroSense had cash and cash equivalents of $2.6 million. The company's financial statements have been prepared on a going concern basis, and it has been indicated that existing cash will not suffice for the next 12 months without additional financing. NeuroSense's lead product candidate, PrimeC, is in development for treating neurodegenerative diseases such as ALS, with ongoing clinical trials and regulatory processes. The company has not generated any revenue to date and expects to continue incurring losses as it invests in product development and seeks regulatory approvals.
NeuroSense Therapeutics, a clinical-stage biotechnology company, reported a net loss of $10.1 million for the year ended December 31, 2023, compared to a net loss of $10.5 million for the previous year. The company's research and development expenses increased by 30.2% to $7.3 million, primarily due to clinical study costs and an increase in employee numbers. General and administrative expenses slightly decreased by 3.9% to $4.8 million. Financing income netted a gain of $1.9 million, mainly from the revaluation of warrants. As of December 31, 2023, NeuroSense had cash and cash equivalents of $2.6 million. The company's financial statements have been prepared on a going concern basis, and it has been indicated that existing cash will not suffice for the next 12 months without additional financing. NeuroSense's lead product candidate, PrimeC, is in development for treating neurodegenerative diseases such as ALS, with ongoing clinical trials and regulatory processes. The company has not generated any revenue to date and expects to continue incurring losses as it invests in product development and seeks regulatory approvals.
生物技術臨床階段公司NeuroSense Therapeutics報告稱，截至2023年12月31日止年度淨虧損爲1010萬美元，而上一年度淨虧損爲1050萬美元。該公司的研發費用增長了30.2%，達730萬美元，主要是由於臨床研究成本和員工數量增加。一般和管理費用略微減少了3.9%，至480萬美元。融資收入實現了190萬美元的收益，主要來自權證的重新評估。截至2023年12月31日，NeuroSense的現金和現金等價物爲260萬美元。該公司的基本報表已按照持續經營基礎編制，已指出現有現金不足以在未來12個月內支持業務需求，需獲得其他融資。NeuroSense的主要產品候選藥物PrimeC正在開發中，用於治療肌萎縮側索硬化等神經退行性疾病，正在進行臨床試驗和監管流程。該公司至今尚未獲得任何營業收入，並預計在投資產品開發和尋求監管批准方面將繼續產生虧損。
生物技術臨床階段公司NeuroSense Therapeutics報告稱，截至2023年12月31日止年度淨虧損爲1010萬美元，而上一年度淨虧損爲1050萬美元。該公司的研發費用增長了30.2%，達730萬美元，主要是由於臨床研究成本和員工數量增加。一般和管理費用略微減少了3.9%，至480萬美元。融資收入實現了190萬美元的收益，主要來自權證的重新評估。截至2023年12月31日，NeuroSense的現金和現金等價物爲260萬美元。該公司的基本報表已按照持續經營基礎編制，已指出現有現金不足以在未來12個月內支持業務需求，需獲得其他融資。NeuroSense的主要產品候選藥物PrimeC正在開發中，用於治療肌萎縮側索硬化等神經退行性疾病，正在進行臨床試驗和監管流程。該公司至今尚未獲得任何營業收入，並預計在投資產品開發和尋求監管批准方面將繼續產生虧損。
有用
沒用
譯文內容由第三人軟體翻譯。
牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生，只对除中国内地以外的地区提供。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
風險及免責聲明
牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生，只对除中国内地以外的地区提供。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
我知道了
風險及免責聲明
牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生，只对除中国内地以外的地区提供。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
我知道了